arsenic trioxide has been researched along with anisomycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emi, N; Iida, S; Kajiguchi, T; Naoe, T; Ueda, R; Yamamoto, K | 1 |
| Guo, W; Lu, XC; Ren, TT; Tang, GQ; Zhang, S; Zhao, FL | 1 |
2 other study(ies) available for arsenic trioxide and anisomycin
| Article | Year |
|---|---|
Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Protein Synthesis Inhibitors | 2006 |
Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Topics: Anisomycin; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cytoskeleton; Humans; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase Inhibitors; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Sarcoma, Ewing | 2012 |